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ABSTRACT
Introduction As the largest and most rapidly ageing 
population, Chinese people are now the major driver of 
the continued growth in dementia prevalence globally. 
The need for evidence- based interventions in Chinese 
communities is urgent. Although a wide range of 
pharmacological and non- pharmacological interventions 
for dementia have been trialled in Chinese populations, 
the evidence has not been systematically synthesised. 
This systematic review and meta- analysis aims to map out 
the interventions for people living with dementia and their 
carers in Chinese communities worldwide and compare 
the effectiveness of these interventions.
Methods and analysis This protocol followed the 
Preferred Reporting Items for Systematic Review and 
Meta- Analysis Protocols checklist. We will search Chinese 
(China National Knowledge Infrastructure, WanFang 
DATA) and English bibliographical databases (MEDLINE, 
EMBASE, PsycINFO, CINAHL Plus, Global Health, WHO 
Global Index Medicus, Virtual Health Library, Cochrane 
CENTRAL, Social Care Online, BASE, MODelling Outcome 
and cost impacts of interventions for DEMentia (MODEM) 
Toolkit, Cochrane Database of Systematic Reviews), 
complemented by hand searching of reference lists. 
We will include studies evaluating the effectiveness of 
interventions for dementia or mild cognitive impairment in 
Chinese populations, using a randomised controlled trial 
design, and published between January 2008 and June 
2020. We will use a standardised form to extract data and 
Version 2 of the Cochrane risk- of- bias tool for randomised 
trials to assess the risk of bias of the included studies. 
Collected data will be fully interpreted with narrative 
synthesis and analysed using pairwise and network meta- 
analyses to pool intervention effects where sufficient 
information is available. We will perform subgroup 
analysis and meta- regression to explore potential reasons 
for heterogeneity.
Ethics and dissemination No formal ethics approval is 
required for this protocol. The findings will facilitate the 
development of studies on interventions for dementia and 
timely inform dementia policymaking and practice. Planned 
dissemination channels include peer- reviewed publications, 
conference presentations, public events and websites.
PROSPERO registration number CRD42019134135.
INTRODUCTION
Around 50 million people currently live 
with dementia worldwide, of whom 20% 
are Chinese populations.1 Chinese popula-
tion refers to people of Chinese ethnicity or 
national heritage, regardless of their nation-
ality or region of residence. As the largest and 
most rapidly ageing population, the Chinese 
Strengths and limitations of this study
 ► This systematic review and meta- analysis will be the 
first review of randomised controlled trials (RCTs) on 
the effectiveness of both pharmacological and non- 
pharmacological interventions for people living with 
dementia and their carers in Chinese communities 
worldwide.
 ► We will use a comprehensive search strategy of 
publications in both Chinese bibliographical data-
bases (China National Knowledge Infrastructure, 
WanFang DATA) and English bibliographical data-
bases (MEDLINE, EMBASE, PsycINFO, CINAHL Plus, 
Global Health, WHO Global Index Medicus, Virtual 
Health Library, Cochrane CENTRAL, Social Care 
Online, BASE, MODelling Outcome and cost impacts 
of interventions for DEMentia (MODEM) Toolkit, 
Cochrane Database of Systematic Reviews).
 ► We will narratively synthesise the collected data to 
map out the dementia- related interventions studied 
in Chinese communities and conduct pairwise and 
network meta- analyses to compare the effective-
ness of interventions.
 ► This review will be limited by the number and quality 
of RCTs conducted in Chinese communities.
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are now the major driver in the continued growth of 
global dementia prevalence.2 Due to the physical and 
emotional challenges involved in caring, dementia affects 
not only people living with the condition but also their 
families, formal carers and other supporters.3 With a 
culture emphasising filial piety, coupled with insufficient 
care services, family care is often the main supporting 
resource for people living with dementia (PLwD) in 
Chinese communities worldwide. Dementia has been 
recognised as one of the most burdensome diseases 
among Chinese populations.4
There is currently no cure for dementia, although 
symptoms can be managed with effective intervention 
and good care.3 China recently launched its national 
dementia strategy, one of whose main tasks is to improve 
the well- being of PLwD by increasing service provision.5 
Taiwan updated its dementia policy in 2017, promoting 
dementia research, innovation and development as one 
of its seven strategies.6 In Macau’s 10- year Plan of Action 
on Dementia Services published in 2016, strengthening 
community services and caregiver support comprises 
one of its five strategies.7 In Hong Kong, a government 
service review and programme plan published in 20178 9 
highlighted the need to strengthen services for PLwD and 
recommended a seven- stage model for dementia service 
following the WHO and Alzheimer’s Disease Internation-
al’s framework.10 The need for evidence- based interven-
tions and care services in Chinese populations is urgent.
Studies on dementia interventions appear to be scarce in 
Asian populations.2 Most evidence on drug treatment and 
non- pharmacological interventions has been generated in 
Western countries, with questionable relevance for Chinese 
populations. For example, cognitive stimulation therapy 
(CST) used alone or in combination with medication was 
shown to be effective and even cost- effective in improving 
cognition and quality of life,11–14 leading to a recommen-
dation for routine use by England’s National Institute for 
Health and Care Excellence15 and by Alzheimer’s Disease 
International.16 In contrast, preliminary findings from a 
study applying CST with Hong Kong Chinese suggest that 
a larger number of participants needed to be treated to 
achieve clinically significant improvement in cognition.17 
Such discrepancies in an intervention’s effect, possibly due 
to cultural differences, highlight the importance of gener-
ating evidence on the effectiveness of dementia- related 
interventions relevant to local populations.
There is now increasing evidence on a wide range of 
interventions for dementia undertaken in Chinese popu-
lations. A few reviews have been published, focusing on 
specific interventions and subtypes of dementia, such 
as the efficacy of donepezil in Chinese with Alzheimer’s 
disease,18 Chinese herbal medicine as adjunctive therapy 
for vascular dementia19 and traditional Chinese mind- 
body exercise (baduanjin) in older adults with mild cogni-
tive impairment (MCI).20 Growing evidence also suggests 
that the therapeutic response to dementia interven-
tion (eg, donepezil) might differ between Chinese and 
Western populations due to pharmacogenetic factors,18 21 
thus emphasising the need for more accurate evaluations 
of interventions tailored to Chinese populations.22
Some existing and ongoing studies aim to synthesise 
evidence for dementia intervention and care, including 
the Modelling Outcome and Cost Impacts of Interven-
tions for Dementia (MODEM) project23 with a dementia 
evidence toolkit (https://www. modem- dementia. org. 
uk/) covering dementia interventions in English liter-
ature and the Strengthening Responses to Dementia 
in Developing Countries (STRiDE) project (https:// 
stride- dementia. org/) with an ongoing systematic review 
and meta- analysis on the evidence in seven low- and 
middle- income countries.24 There is no comprehensive 
evidence synthesis on the effectiveness of dementia or 
dementia- related interventions that cover different types 
of dementia (eg, Alzheimer’s disease, vascular dementia, 
frontotemporal dementia, Lewy body disease and mixed 
dementia) and interventions (eg, pharmacological treat-
ment, psychosocial intervention and traditional Chinese 
medicine) conducted in Chinese populations. Existing 
systematic reviews have focused mainly on the English 
literature, where evidence from high- income areas such 
as Hong Kong and Taiwan can be found. Although 
Chinese academic databases have been recognised as a 
valuable resource for dementia- related studies, they have 
not been fully explored.25–27
To our knowledge, this will be the first systematic review 
and meta- analysis to comprehensively synthesise and 
assess the evidence on the effectiveness of interventions 
for PLwD and their carers among Chinese populations 
in Chinese and English bibliographical databases. We 
aim to (1) map out interventions for dementia studied in 
Chinese communities, and (2) compare the effectiveness 
of those interventions for achieving desired outcomes. 
This study will contribute to shape the understanding of 
existing evidence on effectiveness of dementia- related 
interventions, improve quality of life of PLwD and their 
carers and provide valuable information for practice, 
policymaking and further research. As part of a research 
project, Tools to Inform Policy: Chinese Communities 
Actions in Response to Dementia (TIP- CARD; www. 
tip- card. hku. hk/), this study also aligns with the above- 




This protocol for this systematic review and meta- analysis 
followed the Preferred Reporting Items for Systematic 
Review and Meta- Analysis Protocols checklist.28 This study 
has been registered on the PROSPERO platform ( www. 
crd. york. ac. uk/ prospero).
Eligibility criteria
Population
We will include studies conducted among adults (aged 18 
years and over) living with dementia or MCI and their 
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carers in Chinese populations. We will include relevant 
studies conducted in any type of care settings, such as 
home, community, residential homes, clinics, hospitals 
and other care settings. Participant characteristics such 
as gender, education and age at diagnosis will not be used 
for excluding studies.
We will include studies covering people living with 
any type and stage of dementia. Dementia, as a major 
neurocognitive disorder, describes a group of symp-
toms of cognitive decline, including, but not limited 
to, Alzheimer’s disease, vascular dementia, frontotem-
poral dementia, Lewy body disease and mixed dementia. 
Studies conducted among people living with MCI, mild 
neurocognitive disorder, vascular cognitive impairment 
and no dementia will be eligible for inclusion due to 
the higher risk of developing dementia in later years.29 
We will also include studies conducted among people 
with diseases cooccurring with dementia or MCI, and 
people with dementia or MCI with unknown subtype, as 
long as the diagnostic criteria for dementia or MCI were 
explicated.
Our definition of dementia carer refers to persons 
involved in care provision and management and will not 
depend on whether or not the carer is paid, lives with the 
person they care for or provide direct or indirect care. 
Therefore, dementia carers include health and social 
care professionals, care managers, care workers, admin-
istrative staff of care facilities, family carers, other unpaid 
carers and family members assisting with care decisions. 
We will focus on studies conducted among people of 
Chinese ethnicity or national heritage regardless of their 
nationality or location of residence. Studies without 
explicating the proportion of Chinese participants over 
50% or studies without a specific subgroup analysis for 
Chinese participants will be excluded.
Intervention
Based on the effectiveness perspective,24 30 any type of 
interventions for improving desired outcomes will be 
eligible. We will include studies on pharmacological 
treatment, non- pharmacological intervention (eg, cogni-
tive intervention, technological intervention, training 
and exercise) or multicomponent interventions. We will 
exclude studies: (1) where no clear intervention was 
described, (2) on primary prevention of dementia and 
(3) on non- interventional studies.
Comparison
Given the broad range for interventions of interest, any 
comparisons within the context of eligible study design 
will be acceptable for inclusion, such as active compara-
tors, treatment as usual, placebo and no treatment.
Outcomes
Any type of outcomes of dementia- related intervention will 
be eligible for inclusion from the perspective of effective-
ness, which may affect individuals, families, the dementia 
care workforce, wider society and social or healthcare 
systems. Dementia often triggers complex problems in 
many domains.22 According to the MODEM dementia 
evidence toolkit (https://www. modem- dementia. org. 
uk/), outcomes measured in existing studies may include 
(1) cognition, behavioural and psychological symptoms, 
functional status, physical health and quality of life of 
PLwD, (2) carer burden, carer’s mental health, quality of 
life and other carer outcomes (eg, financial burdens), (3) 
service use, cost reduction (including hospital use reduc-
tion and care home admission delay) and service satisfac-
tion, (4) risk reduction (of dementia and comorbidities) 
and prevention or management of comorbidities. To 
capture the diversity of interventions trialled in Chinese 
communities, we will accept all outcome measures that 
reflect intervention effectiveness.
Study design
To identify potential causal relationships, we will only 
include studies using randomised controlled trial (RCT) 
or cluster RCT designs. To control study quality, we will 
only include RCTs with a low risk of bias (RoB) in the 
process of evidence generation. According to Version 2 of 
the Cochrane RoB tool for randomised trials,31 methods, 
used for generating random allocation sequence indi-
cating low RoB, include computer- generated random 
numbers, a random number table, coin tossing, shuffling 
cards or envelopes, throwing dice or drawing lots. Studies 
that use no random element or provide no information 
on the generation process of the random allocation 
sequence will be excluded.
To minimise small- study effects,32 33 we will exclude 
studies with a sample size of less than 50 in either the 
intervention group or comparison group(s) for the 
eligible population. For studies conducted with a popu-
lation of mixed ethnicity, the sample size of each study 
arm for Chinese subgroup analysis should be greater than 
50 participants. For studies in which more than 50% of 
participants are Chinese and all participants are randomly 
grouped, the sample size of each study arm is expected to 
be greater than 50 participants regardless of ethnicity.
Publication type
We will include the primary publications of intervention 
studies and grey literature evaluating the effectiveness of 
dementia- related interventions in Chinese populations. 
Relevant systematic reviews or scoping reviews will be 
included in the first step of screening and then will be 
used to complement the primary publications by hand 
searching of reference lists. Conference abstracts will be 
included if they contain sufficient information to assess 
eligibility for inclusion.
Publication period
Studies published between January 2008 and June 2020.
Language
Studies will be limited to English and Chinese publications.
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Information sources
We will search two major Chinese bibliographical data-
bases (China National Knowledge Infrastructure and 
WanFang DATA) and English bibliographical databases 
(MEDLINE, EMBASE, PsycINFO, CINAHL Plus, Global 
Health, WHO Global Index Medicus, Virtual Health 
Library, Cochrane CENTRAL, Social Care Online, BASE, 
MODEM Toolkit, Cochrane Database of Systematic 
Reviews). Hand searching of reference lists among review 
studies will complement the database searches.
Search strategy
We will adapt an established search strategy protocol24 
used to search for English language literature. Corre-
sponding Chinese search terms have been translated and 
adapted by three bilingual researchers (GW, SC and CS) 
experienced in dementia/ageing research with a training 
background in psychology, psychiatry, translation, social 
work and social policy from Hong Kong and mainland 
China. Search terms in English and Chinese are listed 
in table 1. In studies published in English, the search 
terms related to Chinese populations include ‘China’, 
‘Chinese’, ‘Sino’, ‘Hong Kong’, ‘Taiwan’, ‘Taiwanese’, 
‘Macau’ and ‘Asian’.
For studies published in English, we will first extract 
eligible study records identified from an ongoing system-
atic review,24 which used the same search strategy and 
search terms for dementia intervention and covered 
studies published between 2008 and 2018. Then, we will 
search these terms for Chinese populations in the title, 
abstract and keywords. Second, we will repeat the English 
bibliographical database search mentioned above to 
identify studies published between January 2019 and June 
2020.
For studies published in Chinese, we will use Python,34 
a programming language, to facilitate Chinese bibli-
ographical database searching by using dementia- related 
search terms (search items number 1–4 in table 1). This 
is because of the technical challenge posed by limitations 
on the number of search terms and exported records per 
time in the two Chinese bibliographical databases. The 
search results for dementia- related study records will be 
exported in a Microsoft Excel spreadsheet. Then, we 
will search the intervention- related terms (search items 
number 5–53) in the title and abstract.
Study records
Data management
To deal with a potentially large number of search results 
and various data sources in two languages, we will manage 
references using two web- based software packages during 
the review and extraction process: (1) Rayyan (https:// 
rayyan. qcri. org/), a web and mobile app that can facil-
itate the initial screening of abstracts and titles using a 
semiautomated process35 and (2) Covidence (https://
www. covidence. org/), an internet- based software plat-
form for managing systematic reviews, including study 
selection, RoB assessment and data extraction.
Duplicate publications will be checked based on title, 
author, journal and year using Microsoft Excel, and the 
‘Find duplicates’ function in Rayyan and Covidence. 
Multiple publications from the same study will be iden-
tified based on the key information (eg, authors’ names, 
study design, intervention and outcomes) from the full 
texts or by contacting authors for clarification if needed. 
Once confirmed, included multiple publications will be 
linked on Covidence.
Study selection
Study selection will be a two- step process, with detailed 
explanations for inclusion and exclusion criteria in each 
step. First, two researchers will independently screen the 
title and abstract and determine the study’s inclusion or 
exclusion on Rayyan. A justification (criterion) will be 
required for any exclusion decision. Studies with insuf-
ficient information in the title and abstract to enable a 
decision to be made will be included at this stage. The 
Rayyan machine learning- based classifier35 will be consid-
ered to facilitate the title and abstract screening, given 
the potentially work overload. Using a certain number of 
manually screened studies as a training data set, Rayyan 
will generate a relevance rating for each study, ranging 
from 0.5 (lowest) to 5 (highest).35 We may use a low rele-
vance score (eg, below 1.5) as a threshold to guide study 
exclusion.
Second, studies included after title and abstract 
screening will be uploaded to Covidence for full- text 
review by two independent reviewers, who will provide a 
justification for each excluded study. Review studies will 
be excluded at this stage, although their reference lists 
will be used to complement the database search results.
All disagreements in each step will be resolved through 
discussion between the two reviewers. If consensus is 
unreachable, a third reviewer will be consulted for a final 
decision.
Reviewers for title and abstract screening and full- text 
review will be able to read and understand inclusion/
exclusion criteria for publications in both English and 
simplified Chinese.
On completion of the selection process, we will generate 
a Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses flowchart36 to illustrate the inclusion and 
exclusion of studies at each stage in study selection.
Data collection process
We will use a standardised form based on the template 
available from Covidence for data extraction that will be 
pilot tested using included studies. To ensure data consis-
tency across reviewers, we will organise exercises and 
group discussions for reviewer training. Due to the antici-
pated large number of potentially eligible studies, the data 
extraction form will be completed by one reviewer and 
verified by the second reviewer. We will keep all records 
of corrections or amendments to the data extraction. For 
studies that do not report the required information, we 
will contact the authors to request information.
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Table 1 Search terms related to dementia and intervention in English and simplified Chinese
Search 
number Search terms in English Search terms in simplified Chinese
1 Dementia 痴呆 or 失智 or 认知症
2 Cognitive disorder 认知障碍or认知功能障碍or认知紊乱or认知功能紊乱
3 Alzheimer 茨海默 or兹海默
4 ((cognit* or memory or cerebr*) adj3 (impair* or los* or declin* or 
deteriorat* or degenerat*)).mp.
(认知or记忆or脑) (缺损or缺失or退*化or衰退or 下降 or 损伤 or 恶化 or 损害 
or 退行)
5 (Intervention* or therap* or treatment* or program* or manage* or 
prevent* or diagnos* or polic*).mp.
干预 or 介入 or 治疗 or 疗法 or 方案or 处理 or 预防 or 诊断 or 措施 or 手段 
or 政策or应用 or支持or效果or疗效or观察or价值or临床or分析
6 Cognitive therapy 认知 (治疗or疗法)
7 Cognitive stimulation 认知 (刺激or促进)
8 Cognitive training 认知训练
9 Cognitive rehabilitation 认知 (复康or复健or康复)
10 Drug therapy or pharmacotherapy *药*
11 Cholinesterase inhibitors 胆碱分解抑制剂 or 胆碱酵素抑制剂 or 胆碱酶抑制剂
12 Cholinesterase agent 胆碱分解剂 or 胆碱酵素剂 or 胆碱酶剂
13 (Sedative or tranquili* adj3 (agent* or drug*)).mp. (镇静 or 镇定or 安神 or 安定) (药 or 剂)
14 Antipsychotic or neuroleptic (agent* or drug*) 抗精神病 (药 or 剂)
15 exp Serotonin Reuptake Inhibitors or ssri (血清素 or 5-羟色胺) (再摄取 or 再吸收 or回收) 抑制剂
16 Benzodiazepines 苯二氮平 or 苯二氮卓
17 (memantine or donepezil or rivastigmine or galantamine or souvenaid 
or risperidone or haloperidol or olanzapine or quetiapine or 
citalopram or dextromethorphan or carbamazepine or mirtazapine or 
sertraline or moclobemide or trazodone or melatonin or ramelteon or 
methylphenidate).mp.
(美金刚 or 美金胺) (多奈呱齐 or 多奈呱其) (卡巴拉汀or利斯的明) (加兰他敏or
加兰他明or格兰他明) (智敏捷) (利培酮or 利螺环酮) (氟哌啶醇or氟哌丁苯or氟
哌醇or卤吡醇) (奥氮平) (喹硫平) (西酞普兰) (右美沙芬or右旋美沙酚or右旋美
索芬or右甲吗喃) (卡馬西平or 卡马平 or 卡巴氮平 or 卡巴马平) (米氮平) (舍曲
林) (吗氯贝胺) (曲唑酮) (褪黑素 or褪黑激素) (雷美替胺 or拉米替隆) (哌甲酯 or
派醋甲酯 or盐酸甲酯)
18 Movement Therapy (运动or 动作)
19 (Physical activit* or physical training).mp. (运动or体育 or 体能) (活动 or 训练)
20 (social adj3 activit*).mp. 社交活动 or 社会活动
21 Psychotherapy 心理 (治疗or疗法)
22 (behavio?r* adj3 therap*).mp. 行为 (治疗or疗法)
23 Counseling 辅导 or 咨询
24 ((Psychosocial or psycho social) adj3 (support or interven* or care)).
ti,ab.
(社会心理or社交心理） (支援or治疗or干预or介入or照顾)
25 Alternative medicine (替代or另类) (治疗or疗法or医学or医疗)
26 Chinese medicine 中医 or 中药
27 Acupuncture 针灸or针刺or电针
28 (herb* adj3 (tea or remedy or remedies or medicine*)).ti,ab. 草药or 药草 or药用植物or 草本 or 茶疗
29 Gingko 银杏 or 白果
30 homeopathy (顺势 or 同质 or 同种)
31 ((music or art or aroma or light or photo or pet or pets) adj3 therap*).
ti,ab.
(音乐 or 艺术 or 香薰or 光照or光线or宠物or动物or 舞蹈)
32 Massage 按摩or推拿
33 Mind Body Therapy 身心or 心身 or 正念or冥想
34 Advance directives 预设医疗指示 or 预设指示 or 预前意愿 or 预先指示
35 (Advance? adj3 (care or medical or healthcare) adj3 plan*).mp. (预设 or 预立) (护理计划 or 临终*计划 or 医疗决定)
36 (decision* adj3 (aid* or support)).mp. 决策援助 or 决策辅助 or 决策支持
37 Case Management 个案管理
38 (communicati* adj3 skill* adj3 training).mp. 沟通技巧 (训练 or 培训)
39 (dementia care adj3 map*).mp. 认知障碍症照顾图谱 or 老年痴呆症照顾图谱 or 失智症照顾测绘
40 ((person* or patient*) adj3 cent* adj3 care).mp. (以人为本or 人本 or 以人为中心 or 病人为本) (照顾 or 照护 or 护理 or 治疗 
or 医疗)
41 ((caregiver or carer) adj3 educat*).mp. (照顾者 or 家属or 家庭or照护者or 照料者) 教育
42 Support Groups (支援or支持or互助） (小组 or组）
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We will prepare the data extraction form in English. 
For studies in Chinese, our bilingual reviewers will 
complete data extraction using the original expression in 
Chinese full texts except for the outcome name and brief 
introduction of the intervention, which will be recorded 
in English based on the English abstract if available or 
manual translation. The final extracted evidence from 
both the English and Chinese studies will be verified 
by one bilingual researcher (CS) to ensure consistent 
translation.
Data items
We will extract information on items listed in box 1 from 
the included studies.
Outcomes and prioritisation
In line with our research aims, we will first record all 
types of outcome and outcome measures stated in the 
included studies to map out the dementia- related inter-
ventions conducted in Chinese communities. Due to the 
anticipated number of Chinese studies from an ongoing 
review,24 we will prioritise the following outcomes of 
interest when extracting outcome results from included 
studies.
As dementia is a condition affecting cognition by defini-
tion, we will prioritise outcome on changes in cognition. 
Common assessments for measuring cognitive impair-
ment level or performance include the Mini–Mental State 
Examination (MMSE), the Montreal Cognitive Assess-
ment (MoCA) and the Alzheimer’s Disease Assessment 
Scale- Cognitive Subscale (ADAS- Cog). Given the effects 
of dementia on the ability to organise activities,22 we 
will also focus on changes in functional ability following 
treatment. For example, the Disability Assessment for 
Dementia is designed for evaluating functional ability to 
complete activities of daily living (ADL) and instrumental 
ADL among PLwD.
Caring for a person living with dementia can be very 
stressful, which may lead to a higher level of depression 
or health issues.37 For studies conducted among carers 
of PLwD, we will focus on changes in quality of life 
and carer burden,38 39 as measured by tools such as the 
Search 
number Search terms in English Search terms in simplified Chinese
44 Social Support 社交支援/社交支持/互助组
45 Computer assisted diagnosis 电脑辅助诊断/计算机辅助诊断
46 Telemedicine 远程医疗 or远距医疗 or 远距离医疗
47 Computer Assisted Therapy 电脑辅助治疗or 计算机辅助治疗
48 Mobile Devices 移动设备 or 行动装置
49 ((smart adj2 (phone* or device* or tablet*)) or smartphone*).mp. 智能 (手机or电话or平板电脑) or 智能* or 可穿戴*
50 cognitive aid 认知辅助/认知帮助
51 Reminder 提示 or 提醒
52 Robot 机器人
53 Animal Experiment 动物实验/动物试验
Table 1 Continued
Box 1 Data to be extracted from included studies
General information
 ► Reviewers’ name.
 ► Date of data extraction.
 ► Publication details and identification.
 ► Sponsorship source.
 ► Research site: places (city- level) where the trial was conducted.
 ► Setting (eg, hospital, care home, community).
 ► Study aim(s).
 ► Publication language: Chinese or English.
Methods
 ► Study design.
 ► List of all outcomes with instruments reported in the study.
Population
 ► Inclusion criteria.
 ► Exclusion criteria.
 ► Group differences.
 ► Clinical features (eg, types of dementia, severity and duration of 
dementia).
 ► Baseline characteristics of participants in each study arm or overall 
participants: demographics (eg, age, gender), socioeconomic status 
(eg, education), clinical outcomes if any, number of participants.
Intervention
 ► Description of the intervention(s) and comparator(s), including in-
tervention name, treatment dose, duration, components and how it 
was delivered.
 ► Intervention type (eg, pharmaceutical intervention, traditional 
Chinese medicine, non- pharmacological treatment and multicom-
ponent interventions).
Outcomes
 ► Outcome name including the name of each outcome of interest and 
how it was measured (instruments used).
 ► Outcome type and reported format. The components of reporting 
effect measures are: (1) the effect measure itself (eg, change from 
baseline), (2) a measure of its variance (eg, the SD or the 95% CI), 
(3) the number of participants in the study arm (N).
 ► Scale and direction of effect
Results
 ► Results of outcomes reported in the original study at each time point.
Risk of bias (RoB) information
 ► Judgements based on the criteria of the RoB 2.
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EUROHIS- QOL 8- item index and the Zarit Burden Inter-
view, respectively.
If the outcome of interest or its measure is not reported 
in included studies, we will extract the outcome results 
that are reported as the primary outcome in the original 
included study. Where feasible, we will also be open to 
examining other outcomes evaluated in the included 
studies.
We will extract results of outcomes of interest measured 
at each time point reported in included studies. Neverthe-
less, we will afford preference to the endpoint of the study 
in the main data synthesis. Results at multiple time points 
will be used for subgroup analysis and meta- regression to 
explore the short- term and long- term effects of outcomes.
RoB in individual studies
We will use the Cochrane Collaboration’s recently updated 
RoB tool31 to assess the quality of included studies in Covi-
dence. Two reviewers will make independent judgements 
based on the criteria for judging the RoB. Disagreement 
will be resolved by discussion and arbitrated by a third 
reviewer if consensus is unreachable. For studies that do 
not provide sufficient information in full texts for RoB 
assessment, we will search for the study’s protocol, trial 
registry information or other relevant materials to facil-
itate the judgement. The absence of a prespecified anal-
ysis plan may raise some concerns in the domain for bias 
in selection of the reported result.
Data synthesis
Evidence on dementia- related interventions in PLwDs 
and carers will be analysed separately. Studies of family- 
based or dyadic interventions involving both PLwDs and 
carers will be categorised according to the subject of each 
outcome.
Narrative synthesis
To map dementia- related interventions conducted in 
Chinese communities, we will undertake a narrative 
synthesis to fully interpret the extracted evidence from 
all included studies. We will first describe and summarise 
disease characteristics, features of the intervention, 
number of participants, participant characteristics, 
outcomes, outcome measures and indication of RoB 
assessment in a tabular form. In line with the Guidance 
on the Conduct of Narrative Synthesis in Systematic 
Reviews,40 we will then explore the relationship among 
types of interventions (or details of pharmacological, 
non- pharmacological and multicomponent interven-
tions), outcomes and outcome measures conducted in 
Chinese populations. Idea webbing will be used to visu-
ally describe conceptual linkages through examination of 
extracted data if feasible. The key questions here are what 
(types of) interventions have been conducted in Chinese 
communities, what specific outcomes those interventions 
target and what measures are used for those outcomes. 
We expect to identify research gaps in this field for future 
studies and practices.
Meta-analyses
To compare the effectiveness of interventions for 
outcomes of interest (described in the Outcomes and 
prioritisation section), we will conduct quantitative 
synthesis of treatment effects through meta- analyses where 
sufficient information is available. For a specific outcome, 
we will perform a series of pairwise meta- analyses for all 
direct comparisons (eg, one comparison between an 
intervention group and a control or another interven-
tion group).41 Due to the underlying difference between 
studies in terms of participants, intervention details and 
care settings, a random- effects pooling model will be 
conducted by default for an overall summary estimate 
by weighting studies using a combination of within- study 
and between- study variance. When the included studies 
use different instruments to evaluate the same outcome 
(eg, MMSE, MoCA and ADAS- Cog for measuring cogni-
tion), we will use standardised mean difference (the abso-
lute mean difference between the intervention group and 
control group divided by the SD in the control group) for 
continuous outcomes and relative risks for dichotomous 
outcomes to compute the effect size for each study.
To compare the effectiveness for multiple interven-
tions, we will use network meta- analysis to combine direct 
and indirect evidence for relevant treatment effects.42 In 
network meta- analyses, different comparisons among two 
or more of the treatments can be included in one anal-
ysis. We will generate network geometry to visualise and 
assess the treatment networks and estimate and combine 
comparative effects from direct and indirect evidence. In 
examining the transitivity hypothesis of network meta- 
analysis, we will use ‘loop- specific approaches’ to detect 
the inconsistency of a network of interventions, including 
local inconsistency test to evaluate the loop inconsistency 
in regions of network separately43 and global incon-
sistency test to evaluate the incoherence in the overall 
network.44
Sensitivity analyses will be conducted to explore the 
robustness of the meta- analysis results by varying the 
analytic data or methods, including analysing studies only 
with a low RoB and trials using a placebo as a comparator.45
Dealing with missing data
When there are missing data, we will attempt to obtain 
these by contacting the study author(s). If unsuccessful, 
we will consider using imputation methods to impute the 
missing value46 or exclude studies with missing data from 
the quantitative analysis. We will use sensitivity analysis to 
evaluate the potential influence on the overall treatment 
effects of included studies that use per- protocol analysis 
or suggest that the result was biased by missing outcome 
data (ie, high RoB) based on the RoB 2 assessment tool.31
Subgroup analysis and meta-regression
We will calculate Cochrane’s Q statistic and the I2 statistic 
to estimate the heterogeneity of the included studies.47 
If statistical heterogeneity is observed, we will conduct 
subgroup analysis and meta- regression to explore the 
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potential reasons for the differences. Potential candi-
date covariates for subgroup analysis and meta- regression 
include intervention characteristics (eg, types of inter-
vention, intervention dosage and duration), participant 
characteristics (eg, age, gender, education, severity of 
dementia and type of dementia), care settings, follow- up 
period (eg, at 3, 6 and 12 months) and locations (eg, 
mainland China, Hong Kong, Taiwan, Macau and other 
Chinese communities worldwide).
Meta-bias(es)
For each meta- analysis, we will use a funnel plot asym-
metry assessment to detect meta- biases. Statistical tests 
for funnel plot asymmetry will be performed when at 
least 10 studies included in the meta- analysis.48 Contour 
lines indicating various statistical significance will be 
used to aid visual interpretation of funnel plots. If funnel 
plot asymmetry is observed, we will also consider other 
possible reasons apart from non- reporting bias such as 
poor methodological quality and true heterogeneity of 
the included studies.49
Confidence in cumulative estimate
We will use the Grading of Recommendations Assess-
ment, Development and Evaluation approach50 to assess 
the quality of evidence. The domains of the assessment 
include RoB, inconsistency, indirectness of evidence, 
imprecision and publication bias.
Patient and public involvement
Neither patients nor the public will be involved in the 
design or development of this review protocol. However, 
stakeholders, including PLwD, family members, care 
staff, healthcare professionals and policymakers, will be 
engaged in the dissemination plan as described below.
ETHICS AND DISSEMINATION
This protocol for a systematic review and meta- analysis 
describes the methods to identify and synthesise published 
evidence on the effectiveness of interventions for PLwD 
and their carers in Chinese communities. No formal 
ethics approval is required for this protocol. The findings 
from this study will facilitate the development of studies 
on interventions for dementia and provide timely infor-
mation for dementia policymaking and practice. We will 
target both professionals and non- specialist audiences in 
disseminating the outcomes of the review through prints 
and events, including peer- reviewed publications, confer-
ence presentations, public events, and publicly accessible 
websites.
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